Treatment outcomes and its trends amongst drug-resistant Mycobacterium tuberculosis patients treated under programmatic conditions in Bengaluru city (2017-2020)

  • Sanjay Singh OPJS University, Churu, Rajasthan
  • Dr. Rakhee P. Kelaskar Professor, Public Health, OPJS University, Churu, Rajasthan
Keywords: Tuberculosis, DR TB, MDR RR TB, PMDT, NTEP, Treatment outcomes, Bengaluru

Abstract

Background

India is having 27% of the world’s drug-resistant TB burden. To address this emerging public health concern PMDT services were rolled out in the year 2007 and nationwide coverage was achieved in the year 2013. In India, MDR RR TB patients who started on second-line treatment in the years 2018 and 2020 under PMDT had favourable treatment outcomes of 56% and 57% respectively. Therefore, the study was conducted to determine the treatment outcomes in patients of DR TB & MDR RR TB in Bengaluru city Karnataka, India.

 

Methods

This was a descriptive cross-sectional study using programmatic data among the notified TB cases during the year 2017-2020 under NTEP of Bengaluru city. Socio-demographic data, clinical characteristics and diagnostic data were studied. Data analysis was conducted in Python (version 3.9.4) to ascertain the treatment outcomes and their trend in the study area.

 

Results and conclusions

A total of 689 patients were identified as DR TB cases having resistance to any first-line anti TB drug during the year 2017-2020. The mean age of the DR TB patients was observed as 36.7 years (95% CI: 22.3-51.1). Among them 434(63.0%) were male, 254(36.9%) were female and 01(0.1%) were transgender. The study revealed the favourable treatment outcomes of 56.6% among the overall DR TB patients and 42.2% among the MDR RR TB patients in Bengaluru city. The study depicted trends of improvements in the successful treatment outcomes among overall DR TB patients from the year 2017 to 2020, but on the other hand, the same among the MDR RR TB patients is a cause of concern. The study highlights adopting a multipronged scheme focusing on the End TB strategy by improving diagnostic capability, assuring high-quality treatment and averting drug resistance propagation among drug-sensitive patients which is central to meeting the challenge of DR-TB in India.

Downloads

Download data is not yet available.

Author Biographies

Sanjay Singh, OPJS University, Churu, Rajasthan

PhD Public Health, Research Scholar

Dr. Rakhee P. Kelaskar, Professor, Public Health, OPJS University, Churu, Rajasthan

Professor, Department of Health Research, OPJS University Churu, Rajasthan

References

1. Central TB Division, Directorate General of Health Services. Ministry of Health and Family Welfare, New Delhi. TB India -2019. Revised National Tuberculosis Control Programme. Annual Status Report. 2019.
2. World Health Organisation: Global Tuberculosis Report. 2019. India
3. Engaging private health care providers in TB care and prevention: a landscape analysis WHO/CDS/TB/2018.33.https://www.who.int/tb/publications/2018/PPMLandscapeAnalysis.pdf
4. World Bank Group. India: Program towards Elimination of Tuberculosis (P167523). Technical Assessment Report December 18, 2018. https://documents1.worldbank.org/curated/en/150891551214323148/pdf/Final-Technical-Assessment-Program-Towards-Elimination-of-Tuberculosis-P167523.pdf
5. World Health Organisation: Global Tuberculosis Report. 2021. India https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_&entity_type=%22country%22&lan=%22EN%22&iso2=%22IN%22
6. Ministry of Health and Family Welfare, Government of India : India TB Report 2022. https://tbcindia.gov.in/WriteReadData/IndiaTBReport2022/TBAnnaulReport2022.pdf
7. Directorate of Census Operations Karnataka. District Census Handbook – Bengaluru. Census of India 2011. Series 30. part XIIA. p. 31. Accessed on 28/02/2020.
8. National TB Elimination Programme, Central TB Division, Ministry of Health and Family Welfare, Government of India: Guidelines for Management of Programmatic Management of Drug Resistant TB in India, March 2021. https://tbcindia.gov.in/showfile.php?lid=3590
9. Dzeyie KA, Basu S, Dikid T, Bhatnagar AK, Chauhan LS, Narain JP. Epidemiological and behavioural correlates of drug-resistant tuberculosis in a Tertiary Care Centre, Delhi, India. Indian J Tuberc. 2019; 66 : 331-6.
10. Bhatt G, Vyas S, Trivedil K. An epidemiological study of multidrug resistant tuberculosis cases registered under Revised National Tuberculosis Control Programme of Ahmedabad city. Indian J Tuberc. 2012; 59 : 18-27.
11. Sharma N, Khanna A, Chandra S, Basu S, Chopra KK, Singla N, Babbar N, Kohli C. : Trends & treatment outcomes of multidrug-resistant tuberculosis in Delhi, India (2009-2014) : A retrospective record-based study. Indian J Med Res. 2020. 151(6). 598-603.
12. Nair D, Velayutham B, Kannan T, Tripathy JP, Harries AD, Natrajan M, et al. : Predictors of unfavourable treatment outcome in patients with multidrug-resistant tuberculosis in India. Public Health Action 2017; 7 : 32-8.
13. Kumar A, Singh AK, Upadhyay V, Pandey J. : Epidemiology of multi-drug-resistant tuberculosis in Northern India. Biomed Biotechnol Res J. 2018. 2(2). 112-21.
14. Chatterjee S, Poonawala H, Jain Y. : Drug-resistant tuberculosis: is India ready for the challenge? BMJ Glob Health. 2018. 3. e000971.
Published
2022-07-07
How to Cite
1.
SINGH S, Kelaskar RP. Treatment outcomes and its trends amongst drug-resistant Mycobacterium tuberculosis patients treated under programmatic conditions in Bengaluru city (2017-2020). Int Arch BioMed Clin Res [Internet]. 2022Jul.7 [cited 2022Nov.30];8(2):CM1-CM5. Available from: https://iabcr.org/index.php/iabcr/article/view/794
Section
ORIGINAL ARTICLES ~ Community Medicine